Mirum Pharmaceuticals (#MIRM) is set to report topline Phase 3 AZURE-1 results for brelovitug in chronic hepatitis delta (HDV) on September 28. 🔹 Key Highlights 🧪 Phase 3 AZURE-1 topline results are due September 28. 🩺 The study evaluates brelovitug in patients with chronic hepatitis delta. 📊 Mirum will also report 48-week results from the Phase 2b portion of the study. 💊 Brelovitug is a late-stage monoclonal antibody program targeting chronic HDV. 📞 Investor call scheduled for 8:30 a.m. ET to present the Phase 3 data. 🔎 The readout represents an important clinical milestone for Mirum's HDV program. 💡 Why It Matters The AZURE-1 readout provides an important clinical update for brelovitug as Mirum advances its late-stage hepatitis delta program. The Phase 3 data could provide further information on the drug's development path in chronic HDV. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified